Novotech Releases Report on Current State of Triple-Negative Breast Cancer Clinical Trials
Novotech, the leading global full-service clinical Contract Research Organization (CRO), has released a comprehensive report analyzing the global clinical trial and drug development landscape for Triple-Negative Breast Cancer (TNBC). The report highlights significant advancements in therapeutic strategies, regional clinical trial activity, and evolving biomarkers driving innovative TNBC treatments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113960593/en/
A Highly Aggressive Breast Cancer Subtype
TNBC, representing 10-15% of breast cancer cases worldwide, is characterized by the absence of key receptors (ER, PR, HER2), limiting the efficacy of targeted hormonal therapies. Despite advances, TNBC remains associated with poor survival rates, with metastatic cases exhibiting five-year survival of under 12%.
Global Clinical Trial Insights
From 2019 to 2024, over 1,500 clinical trials for TNBC were initiated globally, highlighting a robust commitment to improving patient outcomes. Key findings include:
- Regional Leadership: North America led TNBC trials (39%), followed closely by Asia-Pacific (33%), Europe (21%), and ROW (7%). The United States accounted for 83% of North America’s trials, while China and Australia emerged as regional leaders in Asia-Pacific.
- Biomarker-Driven Research: Novel biomarkers such as BRCA1/2 mutations, PD-L1 expression, and FGFR amplifications are increasingly targeted to drive precision therapies.
- Trial Density & Recruitment: Asia-Pacific’s lower trial density and faster recruitment rates provide unique opportunities for TNBC-focused research, supported by a large and diverse patient pool.
Innovation in Therapeutics
TNBC drug development reflects a multi-stage pipeline, with 78 Phase I, 97 Phase II, and 12 Phase III trials underway. The evolution of therapeutic strategies includes:
- Targeted Therapies: PARP inhibitors, immune checkpoint inhibitors (ICIs), and novel antibody-drug conjugates (ADCs) are transforming treatment paradigms.
- Combination Approaches: Synergistic therapies combining immunotherapy, chemotherapy, and targeted agents are enhancing efficacy.
Significant Opportunity in Asia-Pacific
The Asia-Pacific region, with its genetic diversity and unmet clinical needs, remains a focal point for TNBC trials. Novotech’s presence in key Asia-Pacific markets provides a strategic advantage in accelerating clinical research for novel TNBC therapies.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech and small to mid-size companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Fierce CRO 2024 Excellence Award in Clinical Trial Management and Global Operations, Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena 2024 Excellence Awards in Business Expansion, Innovation and Marketing, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113960593/en/
Contacts
Media
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hero MotoSports Team Rally Secures an Impressive 7 th Place Overall Finish at Dakar Rally 202517.1.2025 22:31:00 EET | Press release
Hero MotoSports Team Rally, the motorsport team of the world’s largest manufacturer of motorcycles and scooters - Hero MotoCorp, has successfully completed the Dakar Rally 2025, reinforcing its position as a formidable force in the world’s toughest rally. The team completed this year’s rally at overall 7th position, registering its second best Dakar performance in nine years, after it finished 2nd overall at the world’s toughest rally last year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250117472643/en/ Hero MotoSports at Dakar Rally Stage 12 (Photo: Business Wire) The team’s young Chilean rider, Nacho Cornejo, delivered a stellar performance, maintaining top-10 standings throughout the rally and securing an overall 7th place finish. Nacho showcased remarkable grit and determination, demonstrating his consistency across the stages. Since Stage 1, he remained in the top-10, climbed to 7th place in Stage 8, and held on to
Qualcomm Announces Quarterly Cash Dividend17.1.2025 16:00:00 EET | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.85 per common share, payable on March 27, 2025, to stockholders of record at the close of business on March 6, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Our proven solutions drive transformation across major industries, and our Snapdragon® branded platforms power extraordinary consumer experiences. Building on our nearly 40-year leadership in setting industry standards and creating era-defining technology breakthroughs, we deliver leading edge AI, high-performance, low-power computing, and unrivaled connectivity. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business, QTL, and the vast majority
Jefferies Clients, Shareholders and Employees Contribute $10 Million to Charities Supporting Los Angeles Wildfire Relief17.1.2025 15:00:00 EET | Press release
Jefferies announced today that it will donate $10 million to charities providing aid for first responders and the people and communities impacted by the wildfires across Los Angeles. The donation includes funds from Jefferies, voluntary contributions from its nearly 6,000 worldwide employees, and proceeds from the firm’s January 16 Doing Good Global Trading Day, which set aside 100% of net global trading commissions for charities. Rich Handler, CEO, and Brian Friedman, President of Jefferies, said: “We are so grateful for how the Jefferies network stepped up to support those in need in Los Angeles. These wildfires have inflicted heartbreaking devastation on communities and so many families, and we hope this donation will help deserving charities provide urgently needed relief.” Organization Charity Description Allocation Los Angeles Fire Department Foundation The LAFD is actively seeking funds to equip LAFD members battling wildfires with tools and supplies. $2,000,000 All Hands and He
SLB Announces Fourth-Quarter and Full-Year 2024 Results, Increases Dividend and Initiates $2.3 billion in Accelerated Share Repurchases17.1.2025 13:50:00 EET | Press release
SLB (NYSE: SLB) today announced results for the fourth-quarter and full-year 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250115789214/en/ The exterior of the SLB headquarters in Houston, Texas. (Photo: Business Wire) Fourth-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeDec. 31, 2024Sept. 30, 2024Dec. 31, 2023SequentialYear-on-yearRevenue $9,284 $9,158 $8,990 1% 3% Income before taxes - GAAP basis $1,387 $1,507 $1,433 -8% -3% Income before taxes margin - GAAP basis 14.9% 16.5% 15.9% -151 bps -100 bps Net income attributable to SLB - GAAP basis $1,095 $1,186 $1,113 -8% -2% $0.77 $0.83 $0.77 -7% - Adjusted EBITDA* $2,382 $2,343 $2,277 2% 5% Adjusted EBITDA margin* 25.7% 25.6% 25.3% 8 bps 33 bps Pretax segment operating income* $1,918 $1,902 $1,868 1% 3% Pretax segment operating margin* 20.7% 20.8% 20.8% -11 bps -12 bps Net income attributable to SLB, excluding charges & credits*
Perpetual Atomics and QSA Global Sign Collaboration Agreement17.1.2025 12:03:00 EET | Press release
Perpetual Atomics is excited to announce this collaboration, which will enable the processing of americium into sealed sources for use in radioisotope power systems, including radioisotope heater units (RHUs) and radioisotope thermoelectric generators (RTGs). This partnership is another step toward supporting sustainable and reliable power solutions for some of the most challenging environments in space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250107229344/en/ Perpetual Atomics Team gathered at the University of Leicester (Photo: Business Wire) A University of Leicester spinout, Perpetual Atomics brings over 20 years of expertise in space nuclear power systems and exploration, delivering innovative, reliable solutions for powering space missions in extreme environments, including "surviving the night." QSA Global, with its extensive expertise in designing and producing commercial radioisotope sealed sources for indust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom